Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07489651 · ClinicalTrials.gov registry record · Phase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
A Phase 2 study, sponsored by Reunion Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT07489651 is a Phase 2 study that is actively recruiting participants, run by Reunion Neuroscience. The registered enrollment target is 64 participants.
The verdict
NCT07489651, a Phase 2 study, is actively recruiting participants, sponsored by Reunion Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Interventions
- DRUG Placebo
- DRUG RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07489651
The ClinicalTrials.gov registry entry for NCT07489651 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reunion Neuroscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07489651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07489651 about?
NCT07489651 is a clinical study titled "RE104 Safety and Efficacy Study in Generalized Anxiety Disorder". The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
What is the current status of trial NCT07489651?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2026-04-20. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07489651?
The interventions under investigation include: Placebo (DRUG), RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT07489651?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.